UNSPSC 51111779: Carfilzomib

A type of proteasome inhibitor

UNSPSC 51111779 Carfilzomib is a Commodity code representing a specific oncology pharmaceutical product that state and local governments procure through pharmacy benefit programs and direct purchasing arrangements. The Texas Health and Human Services Commission issued a Request for Information in April 2026 (RFI No. HHS0017013) to explore vendor capabilities for implementing a Therapeutic Pharmacy Initiative focused on direct-to-manufacturer prescription fulfillment, signaling state interest in alternative contracting models that bypass traditional pharmacy benefit managers and group purchasing organizations for pharmaceutical procurement. The scope of work under this code centers on vendor capacity to establish direct manufacturer relationships, negotiate net-pricing models without rebates, implement outcomes-based agreements, and fulfill product volume requirements for state pharmacy benefit programs serving self-insured employee health plans and government employee and retiree populations.

State health and human services agencies represent the primary buyers under this code. The Texas HHS Commission's April 2026 RFI is the only recent documented activity in the source, indicating limited visibility into current procurement velocity for this specific pharmaceutical commodity across state and local jurisdictions. The RFI functions as a preliminary market-intelligence gathering phase rather than a formal competitive solicitation, designed to inform Texas HHS's future procurement strategy and program design before issuing a formal RFP. No award value, budget range, response deadline extension, or formal evaluation timeline has been announced, and the state has not specified set-aside designations, disadvantaged enterprise restrictions, or incumbent contractor information at this exploratory stage.